Market Overview

UPDATE: Deutsche Bank Initiates Coverage on Alnylam Pharmaceuticals with Buy Rating, $40 PT on Significant Long-Term Value Potential

Related ALNY
Mid-Day Market Update: McDonald's Drops On Weak November Sales; Acceleron Pharma Shares Jump
Mid-Morning Market Update: Markets Mixed; Merck To Buy Cubist Pharmaceuticals For $102/Share
Action in Ebola-Related Stocks (Fox Business)

In a report published Friday, Deutsche Bank analyst Alethia Young initiated coverage on Alnylam Pharmaceuticals (NASDAQ: ALNY) with a Buy rating and $40.00 price target.

In the report, Young noted, “Alnylam is an early stage company that uses a technology called RNA interference that occurs naturally in the body to silence problematic genes in diseases that were previously deemed un-druggable. We believe Alnylam has the chance to unlock significant long-term value as they commercialize their assets in the clinic during 2017 and beyond, leading to $4B+ in unadjusted sales. We initiate with a Buy rating and a $40 target price.”

Alnylam Pharmaceuticals closed on Thursday at $28.06.

Latest Ratings for ALNY

DateFirmActionFromTo
Jan 2014S&P Capital IQUpgradesHoldBuy
Jan 2014Morgan StanleyDowngradesOverweightEqual-weight
Jan 2014S&P Capital IQDowngradesBuyHold

View More Analyst Ratings for ALNY
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Initiation Analyst Ratings

 

Related Articles (ALNY)

Around the Web, We're Loving...

Get Benzinga's Newsletters